Pamela L. Kunz

Medical oncologist, GI specialist

Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center

Gastrointestinal (GI) Cancer Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: Stanford University School of Medicine (2007) CA

Residency: Stanford University School of Medicine (2005) CA

Internship: Stanford University School of Medicine (2002) CA

Residency: Stanford University School of Medicine (2004) CA

Board Certification: Medical Oncology, American Board of Internal Medicine (2010)

Board Certification, Oncology, ABIM (2010)

Board Certification: Internal Medicine, American Board of Internal Medicine (2004)

Medical Education: Dartmouth Medical School (2001) NH

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness
Worhunsky, D. J., Krampitz, G. W., Poullos, P. D., Visser, B. C., Kunz, P. L., & Poultsides, G. A. (2014). Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB, 16(4), 304-311.

Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors
Qadan, M., Ma, Y., Visser, B. C., Kunz, P. L., Fisher, G. A., & Poultsides, G. A. (2014). Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 218(2), 188-195.

Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?
Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., & Poultsides, G. A. (2013). Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?. ANNALS OF SURGICAL ONCOLOGY, 20(5), 1631-1638.

Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors
Kunz, P. L., Reidy-Lagunes, D., Anthony, L. B., Bertino, E. M., Brendtro, K., & Yao, J. C. (2013). Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. PANCREAS, 42(4), 557-577.

Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Shah, M. A., Wainberg, Z. A., Catenacci, D. Vt., Hochster, H. S., Ford, J., & Bottaro, D. P. (2013). Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLOS ONE, 8(3).

Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis
Subramaniam, S., Zell, J. A., & Kunz, P. L. (2013). Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 5-9.

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors
Kunz, P. L., He, A. R., Colevas, A. D., Pishvaian, M. J., Hwang, J. J., & Marshall, J. L. (2012). Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS, 30(6), 2364-2370.

Neoadjuvant Imatinib for Borderline Resectable GIST
Koontz, M. Z., Visser, B. M., & Kunz, P. L. (2012). Neoadjuvant Imatinib for Borderline Resectable GIST. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(12), 1477-1482.

Capecitabine-Induced Chest Pain Relieved by Diltiazem
Ambrosy, A. P., Kunz, P. L., Fisher, G. A., & Witteles, R. M. (2012). Capecitabine-Induced Chest Pain Relieved by Diltiazem. AMERICAN JOURNAL OF CARDIOLOGY, 110(11), 1623-1626.

Long-Term Survivors of Gastric Cancer: A California Population-Based Study
Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., & Clarke, C. A. (2012). Long-Term Survivors of Gastric Cancer: A California Population-Based Study. JOURNAL OF CLINICAL ONCOLOGY, 30(28), 3507-3515.

Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features
Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., & Pai, R. K. (2012). Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. MODERN PATHOLOGY, 25(8), 1128-1139.

Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis
Poultsides, G. A., Huang, L. C., Chen, Y., Visser, B. C., Pai, R. K., & Norton, J. A. (2012). Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis. ANNALS OF SURGICAL ONCOLOGY, 19(7), 2295-2303.

Neuroendocrine Tumors Clinical Practice Guidelines in Oncology
Kulke, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., & Dwyer, M. A. (2012). Neuroendocrine Tumors Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(6), 724-764.

Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., & Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(4), E595-E601.

HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment
Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., & Pai, R. K. (2012). HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(1), 13-24.

SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER
Schellenberg, D., Kim, J., Ciristman-Skieller, C., Chun, C. L., Columbo, L. A., & Koong, A. C. (2011). SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(1), 181-188.

Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal
Bazan, J. G., Hara, W., Hsu, A., Kunz, P. A., Ford, J., & Chang, D. T. (2011). Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. CANCER, 117(15), 3342-3351.

Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection
Norton, J. A., Harris, E. J., Chen, Y., Visser, B. C., Poultsides, G. A., & Jensen, R. T. (2011). Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection. ARCHIVES OF SURGERY, 146(6), 724-732.

F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases
Zissen, M. H., Kunz, P., Subbarayan, M., Chin, F. T., Conti, P. S., & Quon, A. (2011). F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. NUCLEAR MEDICINE COMMUNICATIONS, 32(5), 343-347.

Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma
Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., & Pai, R. K. (2010). Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma. CANCER, 116(22), 5179-5187.

Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer
Minn, A. Y., Hsu, A., La, T., Kunz, P., Fisher, G. A., & Chang, D. T. (2010). Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer. CANCER, 116(16), 3943-3952.

(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY
Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., & Chang, D. T. (2010). (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(5), 1420-1425.

Pathological response after chemoradiation for T3 rectal cancer
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., & Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. COLORECTAL DISEASE, 12(7), E24-E30.

Pathological response after chemoradiation for T3 rectal cancer.
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., & Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. Colorectal disease , 12(7 Online), e24-30.

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
Kunz, P. L., & Fisher, G. A. (2010). Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical and experimental gastroenterology, 3, 79-86.

Multimodality treatment with intensity modulated radiation therapy for esophageal cancer
La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., & Chang, D. T. (2010). Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. DISEASES OF THE ESOPHAGUS, 23(4), 300-308.

Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis
Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., & Koong, A. C. (2009). Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. JOURNAL OF TRANSLATIONAL MEDICINE, 7.

Escherichia coli O157 : H7 infection in nursing homes: Review of literature and report of recent outbreak
Reiss, G., Kunz, P., Koin, D., & Keeffe, E. B. (2006). Escherichia coli O157 : H7 infection in nursing homes: Review of literature and report of recent outbreak. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 54(4), 680-684.

Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus
Vij, R., Triadafilopoulos, G., Owens, D. K., Kunz, P., & Sanders, G. D. (2004). Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. GASTROINTESTINAL ENDOSCOPY, 60(5), 739-756.

Tandem mass spectrometry and newborn screening: Pilot data and review
Filiano, J. J., Bellimer, S. G., & Kunz, P. L. (2002). Tandem mass spectrometry and newborn screening: Pilot data and review. PEDIATRIC NEUROLOGY, 26(3), 201-204.

Molecular analysis and prenatal diagnosis of human fumarase deficiency
Coughlin, E. M., Christensen, E., Kunz, P. L., Krishnamoorthy, K. S., Walker, V., & Shih, V. E. (1998). Molecular analysis and prenatal diagnosis of human fumarase deficiency. MOLECULAR GENETICS AND METABOLISM, 63(4), 254-262.